Matriptase is a type II transmembrane serine protease expressed by cells of surface epithelial origin, including epithelial ovarian tumor cells. Matriptase cleaves and activates proteins implicated in the progression of cancer and represents a potential prognostic and therapeutic target. The aim of this study was to examine the expression of matriptase in ovarian tumors and to assign clinicopathological correlations. Immunohistochemical analysis of matriptase was performed in tissue microarrays of 164 ovarian neoplasms including 84 serous adenocarcinomas, 23 mucinous adenocarcinomas, 10 endometrioid adenocarcinomas, six yolk sac tumors, 12 clear cell carcinomas, six dysgerminomas, eight granulosa cell tumors, four transitional cell carcinomas, five fibromas, and six Brenner tumors. All ovarian tumors except the fibromas and Brenner tumors showed significant expression of matriptase. The matriptase scores were significantly higher in the tumors than in their nontumor counterparts (304+/-26 for serous adenocarcinoma; 361+/-28 for mucinous adenocarcinoma; 254+/-17 for endometrioid adenocarcinoma; 205+/-19 for yolk sac tumor; 162+/-16 for clear cell carcinoma; 109+/-11 for dysgerminoma; 105+/-9 for granulosa cell tumor; and 226+/-18 for transitional cell carcinoma). Matriptase scores in serous adenocarcinoma were correlated with TNM stage and FIGO stage. Our findings demonstrate for the first time that matriptase is overexpressed in many malignant ovarian tumors. It may be a novel biomarker for diagnosis and treatment of malignant ovarian tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/modpathol.3800495 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: this retrospective study aimed to evaluate the impact of BRCA mutational status on the outcomes of patients with advanced ovarian cancer treated with either primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Material and a total of 79 patients with stage III-IV ovarian cancer treated at Elias Emergency University Hospital between January 2014 and March 2024 were included. Patients received either PDS followed by chemotherapy or NACT-IDS.
View Article and Find Full Text PDFTranscriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.
BMC Cancer
December 2024
Department of Gynecology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, 650118, Yunnan, P. R. China.
New treatment strategies for ovarian cancer, which is the deadliest female reproductive tract malignancy, are urgently needed. Here, we investigated the anticancer effects of fenbendazole (FBZ), a benzimidazole compound, on the regulation of apoptosis and mitotic catastrophe in A2780 and SKOV3 human epithelial ovarian cancer cells. Functional experiments, including Cell Counting Kit 8 (CCK-8), colony formation, and flow cytometry assays, were conducted to explore the effects of FBZ on the malignant biological behavior of A2780 and SKOV3 cells.
View Article and Find Full Text PDFAnalysis of MRI imaging characteristics in 10 cases of adult granulosa cell tumor with normal estrogen levels.
BMC Med Imaging
December 2024
Department of Radiology, The Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, Zhejiang, 325000, China.
Objective: This study investigates the MRI characteristics of primary and metastatic adult granulosa cell tumor with normal estrogen levels (AGCT-NEL) to enhance clinical understanding and diagnostic accuracy of this disease.
Methods: We collected clinical data from 10 patients with AGCT-NEL, confirmed by pathology, treated at our hospital from January 2016 to January 2024. We retrospectively analyzed the MRI features of primary and metastatic lesions from aspects such as shape, edge characteristics, MRI signal, and enhancement features.
Diagnostic Value of the Ovarian-Adnexal Reporting and Data System Ultrasound in Ovarian Masses: A Two-Center Study.
Br J Radiol
December 2024
Ultrasound Department, Fourth Affifiliated Hospital of Harbin Medical University, Surgeon's Hall, No. 37, Yiyuan Road, Nangang District, Harbin City, Heilongjiang prov, China.
Objective: This study aimed to assess the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) and Ultrasound (US) and its sub-classification system for distinguishing ovarian masses.
Methods: O-RADS US was used for the retrospective analysis of 606 ovarian masses of Chinese from two medical centers by two gynecologic sonographers with varying experience. The O-RADS 4 categories masses were further sub-classified into O-RADS 4a and O-RADS 4 b through three different approaches(O-RADS A1/A2/A3).
Insights into targeting LKB1 in tumorigenesis.
Genes Dis
March 2025
The Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON N6A 4L6, Canada.
Genetic alterations to serine-threonine kinase 11 () have been implicated in Peutz-Jeghers syndrome and tumorigenesis. Further exploration of the context-specific roles of liver kinase B1 (LKB1; encoded by ) observed that it regulates AMP-activated protein kinase (AMPK) and AMPK-related kinases. Given that both migration and proliferation are enhanced with the loss of LKB1 activity combined with the prevalence of genetic alterations in cancer biopsies, LKB1 was marked as a tumor suppressor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!